David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

As a co-author on these abstracts, Carbone shared insight on the neoadjuvant study of atezolizumab (Tecentriq) before surgical resection in patients with lung cancer. The findings so far show correlation between immune biomarkers and progressive disease or patient response.

Another study presented at WCLC is a retrospective analysis of immunotherapy utilization in small cell lung cancer (SCLC). Carbone states that this study could also show an increase in the use of immunotherapy in SCLC.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Immunotherapy in Lung Cancer

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

IASLC World Conference on Lung Cancer

David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.

Dr. Carbone on Pivotal Immunotherapy Studies in Lung Cancer